Vinod P Balachandran
Overview
Explore the profile of Vinod P Balachandran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
6764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, et al.
Nature
. 2025 Feb;
PMID: 39972124
A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA-lipoplex vaccines against somatic mutation-derived neoantigens may...
2.
Perrin T, McIntyre S, Ehrich F, Heiselman J, van der Stok E, Fiasconaro M, et al.
Ann Surg
. 2025 Feb;
PMID: 39925254
Objective: To enhance understanding of the relationships between margin width, recurrence patterns, recurrence-free survival, and salvage therapy following initial hepatectomy for colorectal liver metastases (CRLM). Background: The prognostic implications of...
3.
Schleimer L, Liu A, Kalvin H, Barekzai A, Choubey A, Jung J, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39875717
Background: A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility of robotic HAIP placement, comparison of outcomes...
4.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39873847
No abstract available.
5.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2501-2502.
PMID: 39873846
No abstract available.
6.
Sharib J, Rhodin K, Liu A, McIntyre S, Bartholomew A, Masoud S, et al.
Ann Surg Oncol
. 2025 Jan;
32(4):2456-2466.
PMID: 39827317
Background: Randomized data suggest improved survival with adjuvant chemotherapy for biliary tract cancers; however, subset analyses of intrahepatic cholangiocarcinoma (IHC) show limited survival benefit. This study evaluated the impact of...
7.
Amisaki M, Zebboudj A, Yano H, Zhang S, Payne G, Chandra A, et al.
Nature
. 2025 Jan;
638(8052):1076-1084.
PMID: 39814891
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ...
8.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2024 Dec;
PMID: 39656390
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease due to its aggressiveness, late-stage diagnosis, and limited treatment options. Microsatellite instability-high (MSI-H) cancers are susceptible to immune checkpoint inhibitors. Survival...
9.
Blair A, Radomski S, Chou J, Liu M, Howell T, Park W, et al.
Ann Surg Oncol
. 2024 Nov;
32(3):1869-1878.
PMID: 39576455
Background: Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the...
10.
Keane F, OConnor C, Moss D, Chou J, Perry M, Crowley F, et al.
J Natl Cancer Inst
. 2024 Oct;
117(3):496-506.
PMID: 39460946
Background: Adjuvant modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). Data are limited on adjuvant modified...